CYTO Stock Forecast – 2022, 2023, 2024, 2025, 2030

Altamira Therapeutics Ltd Stock is surging upwards on Friday on the release of favorable nasal spray medical reports.

Altamira Therapeutics is putting its Bentrio nasal spray to the trial to see whether it may defend against with the Delta version of Covid-19. Because the nasal spray was successful against with the Alpha type, testing against the Delta form were done.

The nasal spray was tested for safety before and after treatment to the Delta version in this trial. When it is used earlier, this resulted in viral titers of -83 percent. The figures for individuals who took it after being treated range from -69 percent to -85 percent.

Founder of Altamira Therapeutics Ltd Stock, chairman, and CEO, Thomas Meyer, stated this in a press statement today that increased CYTO stock price.

Altamira Therapeutics intends to broaden its Bentrio testing against the Delta version. This comprises effectiveness and safety plans for a COVID-19 clinical study. Before beginning this trial, the business is awaiting clearance from the Drugs Controller General of India.

Today’s significant trade in CYTO stock is because to the favorable Covid-19 announcement. Over than 145 million shares of CYTO Stock had been exchanged as of this writing. That is a significant increase over the Altamira Therapeutics Ltd‘s daily average trading volume of around 237,000 shares.

As of Friday morning, CYTO stock was up 67.8 percent.

What Does Altamira Therapeutics Ltd Do?

Altamira Therapeutics Ltd develops pharmaceuticals to address various healthcare problems. Its commercial applications including Bentrio, a drug-free nasal spray for self-protection of airborne infections and allergies.

The firm is also engaged in the development of RNA therapeutic strategies for extrahepatic targeted therapy, such as the OligoPhore and SemaPhore systems for oligonucleotide and mRNA delivery; AM-125, which is also in Phase 2 clinical progress for the intranasal care of vertigo; and Keyzilen, and that is in Phase 3 clinical trials for the treatment of acute inner ear tinnitus; and Sonsuvi, which is now in Phase 3 clinical trials for the treatment of acute inner loss of ear hearing.

It is largely based in Basel, Switzerland. In July 2021, the firm was renamed from Auris Medical Holding Ltd. to Altamira Therapeutics Ltd. Altamira Therapeutics Ltd was established in 2003 and is based in Hamilton, Bermuda.

CYTO Stock Price Today

Current CYTO Stock Price today is $2.33 (+0.81 / 53.29%), with an opening CYTO Stock price at $2.49. The highest CYTO Stock Price is $3.33 and the lowest is $2.14 for today.

Also, you can check the 14-days historical CYTO Stock price data below.

• Market Cap: 29.6 M
• CYTO Stock Price in USD(Previous Close): 2.300
• Share Volume(Previous Close): 193.96 M
• Last CYTO Stock Price in USD: 2.300
• 52 Week Change of CYTO Stock Price:490
• 90-Day Moving Average: 2.155
• 52 Week High: 25
• 52 Week Low: 805
• 50 Day Moving Average: 86
• 200 Day Moving Average: 82

Is Altamira Therapeutics Ltd Stock a Good Buy?

If you’re searching for a high-returning company, CYTO Stock may not be a good, high-risk one-year buy. Current CYTO Stock price is 2.300 USD as of today, however your present purchase may be undervalued in the upcoming years.

CYTO Stock Forecast

Altamira Therapeutics Ltd Stock, as well as its industry trends, have been in a great trend in the previous 12 months, according to current CYTO Stock price data. There appears to be a current pattern in which CYTO Stock in the Manufacturing industry have been successful throughout this timeframe. Some experts of Altamira Therapeutics stock price forecast predict a downward trend in the upcoming term and that CYTO Stock is not a smart investment for profit. Because there is a bad Altamira Therapeutics stock price forecast, we recommend exploring for alternative companies to create a portfolio instead. Investing in downturn industries has always been more difficult, therefore if you are a newbie, you should skip these securities.

Below, you can see the Altamira Therapeutics stock price forecast for upcoming days and weeks based on the data of last 30 days.

• 52 Week High CYTO Stock Forecast: 31.275
• 52 Week Low CYTO Stock Forecast: 0.000001
• 45-Day Moving Average of CYTO Stock price: 2.501
• 90-Day Moving Average of CYTO Stock price: 3.715

Altamira Therapeutics stock price forecast for the next days.

• The CYTO Stock price is 2.300 USD today.
• Based on the Altamira Therapeutics stock price forecast data, CYTO Stock price target in 14 days is $ 2.785 highest and $ 2.095 lowest.
• The CYTO Stock price may fall from 2.300 USD to 0.00618 USD. So that, the change of CYTO Stock price will be -99.731%.

CYTO Stock Forecast 2021, 2022, 2023, 2024, 2025, 2030